1339PDPHASE II TRIAL OF EPIDERMAL GROWTH FACTOR OINTMENT FOR PATIENTS WITH ERLOTINIB-RELATED SKIN EFFECTS

Sung Yong Oh,In Gyu Hwang,Jeeyun Lee,Min Jae Park,Suee Lee,Sung Hyun Kim,Ki-Hoon Song,Choonhee Son,Jung Hun Kang,Myung-Hee Kang,Hoon-Gu Kim,Young Suk Park,Jong Mu Sun,Hyun Jung Kim,Chan-Kyu Kim,Seong Yoon Yi,Joung-Soon Jang,Keunchil Park,Hyo-Jin Kim

1339PDPHASE II TRIAL OF EPIDERMAL GROWTH FACTOR OINTMENT FOR PATIENTS WITH ERLOTINIB-RELATED SKIN EFFECTS

2014

Sung Yong Oh
In Gyu Hwang
Jeeyun Lee
Min Jae Park
Suee Lee
Sung Hyun Kim
Ki-Hoon Song
Choonhee Son
Jung Hun Kang
Myung-Hee Kang
Hoon-Gu Kim
Young Suk Park
Jong Mu Sun
Hyun Jung Kim
Chan-Kyu Kim
Seong Yoon Yi
Joung-Soon Jang
Keunchil Park
Hyo-Jin Kim

Purpose The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). In the present study, we evaluated the effect of epidermal growth factor (EGF) ointment on erlotinib-related skin effects (ERSEs).

Keywords:

Epidermal Growth Factor Ointment
Medicine
Epidermal growth factor
Pathology
Pancreatic cancer
Phases of clinical research
Epidermal growth factor receptor
Erlotinib
Tyrosine-kinase inhibitor
Lung cancer
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations